Search company, investor...
aTyr Pharma company logo

aTyr Pharma

atyrpharma.com

Founded Year

2005

Stage

IPO | IPO

Total Raised

$180.5M

Date of IPO

5/7/2015

Market Cap

0.06B

Stock Price

2.13

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. To protect this pipeline, aTyr built an intellectual property estate comprising 24 patents and over 200 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation, for which there are currently limited or no treatment options.

Headquarters Location

3545 John Hopkins Court Suite 250

San Diego, California, 92121,

United States

858-731-8389

Missing: aTyr Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: aTyr Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing aTyr Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

aTyr Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

aTyr Pharma Patents

aTyr Pharma has filed 1 patent.

The 3 most popular patent topics include:

  • Molecular biology
  • Protein domains
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/5/2019

11/22/2022

Immunology, Clusters of differentiation, Psychotherapy, Drug discovery, Protein domains

Grant

Application Date

4/5/2019

Grant Date

11/22/2022

Title

Related Topics

Immunology, Clusters of differentiation, Psychotherapy, Drug discovery, Protein domains

Status

Grant

Latest aTyr Pharma News

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 18, 2022

San Diego, California, UNITED STATES SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 13,200 shares of its common stock, each with an exercise price of $2.38 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on November 16, 2022, the effective date of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan. Each option vests over a period of four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining 75% vesting in equal monthly installments over three years, subject to the applicable employee’s continued employment with aTyr through each vesting date. The options are subject to the terms and conditions of the aTyr Pharma, Inc. 2022 Inducement Plan and the terms and conditions of an award agreement covering the grant. About aTyr aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com . Contact:

aTyr Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

aTyr Pharma Rank

aTyr Pharma Frequently Asked Questions (FAQ)

  • When was aTyr Pharma founded?

    aTyr Pharma was founded in 2005.

  • Where is aTyr Pharma's headquarters?

    aTyr Pharma's headquarters is located at 3545 John Hopkins Court, San Diego.

  • What is aTyr Pharma's latest funding round?

    aTyr Pharma's latest funding round is IPO.

  • How much did aTyr Pharma raise?

    aTyr Pharma raised a total of $180.5M.

  • Who are the investors of aTyr Pharma?

    Investors of aTyr Pharma include EcoR1 Capital, Rock Springs Capital, Federated Investors, Deerfield Management, Sphera Funds and 10 more.

  • Who are aTyr Pharma's competitors?

    Competitors of aTyr Pharma include Humanetics, Arena Pharmaceuticals, Eyegate Pharmaceuticals, Rigel Pharmaceuticals, Santaris Pharma and 13 more.

Compare aTyr Pharma to Competitors

Neurocure Logo
Neurocure

Neurocure is a specialty pharma company working on psychiatric and central nervous system diseases.

L
Labormed Pharma

LaborMed Pharma, aims to offer modern and accessible treatments for cardiovascular diseases, those affecting the central nervous system, the metabolism a.s.o., medicines produced in a state-of-the-art factory in Bucharest.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

C
Catena Pharmaceuticals

Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.